These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 2864750)

  • 21. Platelet-binding of the von Willebrand factor.
    Green D; Muller HP
    Thromb Haemost; 1978 Jun; 39(3):689-94. PubMed ID: 309191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Von Willebrand factor and platelet adhesion to the subendothelium of the vascular wall].
    Meyer D
    Nouv Rev Fr Hematol (1978); 1982; 24(3):145-51. PubMed ID: 6752879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of platelets, von Willebrand factor, and ristocetin during platelet agglutination.
    Moake JL; Olson JD; Troll JH; Weinger RS; Peterson DM; Cimo PL
    J Lab Clin Med; 1980 Jul; 96(1):168-84. PubMed ID: 6967100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I; Farrugia A; Tran E; Anastasius V; Charnock A
    Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of tryptic fragments of von Willebrand factor involved in binding to thrombin-activated platelets with fragments involved in ristocetin-induced binding and binding to collagen.
    Houdijk WP; Girma JP; van Mourik JA; Sixma JJ; Meyer D
    Thromb Haemost; 1986 Dec; 56(3):391-6. PubMed ID: 3551182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbohydrate on human factor VIII/von Willebrand factor. Impairment of function by removal of specific galactose residues.
    Sodetz JM; Paulson JC; Pizzo SV; McKee PA
    J Biol Chem; 1978 Oct; 253(20):7202-6. PubMed ID: 100492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
    Neugebauer BM; Goy C; Budek I; Seitz R
    Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.
    Houdijk WP; Sakariassen KS; Nievelstein PF; Sixma JJ
    J Clin Invest; 1985 Feb; 75(2):531-40. PubMed ID: 3919060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S; Carlson M; Hillarp A
    Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactivity of small molecular forms of human factor VIII/von Willebrand factor with botrocetin and anti-factor VIII-coated latex particles.
    Furlan M; Perret BA; Beck EA
    Thromb Haemost; 1985 Aug; 54(2):463-5. PubMed ID: 3936216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multimeric structure of platelet factor VIII/von Willebrand factor: the presence of larger multimers and their reassociation with thrombin-stimulated platelets.
    Fernandez MF; Ginsberg MH; Ruggeri ZM; Batlle FJ; Zimmerman TS
    Blood; 1982 Nov; 60(5):1132-8. PubMed ID: 6982084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of the largest platelet-von Willebrand multimers in a patient with lactoferrin deficiency and a bleeding tendency.
    Parker RI; McKeown LP; Gallin JI; Gralnick HR
    Thromb Haemost; 1992 Mar; 67(3):320-4. PubMed ID: 1641822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of calcium-dependent binding of endogenous factor VIII/von Willebrand factor to surface activated platelets.
    Furby FH; Berndt MC; Castaldi PA; Koutts J
    Thromb Res; 1984 Sep; 35(5):501-11. PubMed ID: 6435280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asialo von Willebrand factor binding to and aggregation of platelets: effects of inhibitors of platelet metabolism and function.
    Williams SB; McKeown LP; Gralnick HR
    J Lab Clin Med; 1987 May; 109(5):560-5. PubMed ID: 2437231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of thrombin and ristocetin in the interaction between von Willebrand factor and platelets.
    Harrison RL; McKee PA
    Blood; 1983 Aug; 62(2):346-53. PubMed ID: 6307433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical role of the carbohydrate moiety in human von Willebrand factor protein for interactions with type I collagen.
    Kessler CM; Floyd CM; Frantz SC; Orthner C
    Thromb Res; 1990 Jan; 57(1):59-76. PubMed ID: 2300925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate.
    Samor B; Michalski C; Brandin MP; Andre MH; Chtourou S; Tellier Z
    Vox Sang; 2012 Jul; 103(1):35-41. PubMed ID: 22239246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.